23ME610 by 23AndMe Holding for Metastatic Renal Cell Carcinoma: Likelihood of Approval

23ME610 is under clinical development by 23andMe Holding and currently in Phase II for Metastatic Renal Cell Carcinoma.

Study highlights importance of healthy eating for children’s heart health

A healthier diet is associated with serum metabolite concentrations indicative of better cardiovascular health already in school-aged children, a recent study from the University of

January 16, 2024

Noom Unveils AI-Powered Food Logging and Welli Assistant

What You Should Know: – Noom, the leader in digital health coaching for chronic disease prevention, is revolutionizing its platform with the launch of two

June 28, 2024

ED Clinicians Tackle Patients’ Food Insecurity, Homelessness

PHILADELPHIA — Emergency departments trying to help patients with social problems such as food insecurity and housing insecurity are meeting with varying degrees of success,

October 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.